- CA$39.86m
- CA$53.74m
- CA$10.03m
- 28
- 52
- 29
- 29
Annual balance sheet for LSL Pharma, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
R2011 July 31st | 2012 July 31st | 2021 July 31st | 2022 July 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Interim Report | ARS | ARS | ARS | ARS |
| Standards: | CAS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.183 | 0.117 | 0 | 0 | 0.008 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.02 | 0.091 | 0.017 | 0.025 | 2.68 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 0.217 | 0.21 | 0.017 | 0.026 | 7.2 |
| Net Property, Plant And Equipment | — | 0.002 | — | — | 14.7 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 0.217 | 1.16 | 0.017 | 0.026 | 30.9 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.038 | 0.08 | 0.203 | 0.285 | 15.1 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.038 | 0.08 | 0.203 | 0.285 | 22.2 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 0.178 | 1.08 | -0.186 | -0.26 | 8.65 |
| Total Liabilities & Shareholders' Equity | 0.217 | 1.16 | 0.017 | 0.026 | 30.9 |
| Total Common Shares Outstanding |